Ever since the introduction of highly active antiretroviral therapy (ART) in 1995, HIV infection has been linked to “metabolic” complications (insulin resistance, dyslipidemia, osteoporosis, and others). Studies suggested increased rates of myocardial infarction, renal insufficiency, neurocognitive dysfunction, and fractures in HIV-postitive patients. Even long-term suppression of HIV seemed to be accompanied by an excess of deleterious inflammation that could promote these complications. The aims of this viewpoint paper are to summarize recent data and to examine the possibility that the problem of aging-related morbidity in HIV might not be as dramatic as previously believed.

Keywords:
HIV, Aging, Comorbidities, Comedications, Polypharmacy, Drug interactions, Frailty
1.
Triant VA, Lee H, Hadigan C, Grinspoon SK: Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506–2512.
2.
Triant VA, Brown TT, Lee H, Grinspoon SK: Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008; 93: 3499–3504.
3.
Triant VA, Regan S, Grinspoon SK: MACE incidence among HIV and non-HIV-infected patients in a clinical care cohort. Conference on Retroviruses and Opportunistic Infections, Boston, MA, –March 3–6, 2014. Abstract 738. (Internet) available from www.croiconference.org/sites/all/abstracts/738.pdf (accessed: December 12, 2017).
4.
Freiberg MS, Chang C-CH, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al: HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173: 614–619.
5.
Drozd DR, Kitahata MM, Althoff KN, Zhang J, Grange SJ, Napravik S, et al: Increased risk of myocardial infarction in HIV-infected individuals in North America compared with the general population. J Acquir Immune Defic Syndr 2017; 75: 568–576.
6.
Rasmussen LD, Helleberg M, May MT, Afzal S, Kronborg G, Larsen CS, et al: Myocardial infarction among Danish HIV-infected individuals: population-attributable fractions associated with smoking. Clin Infect Dis 2015; 60: 1–9.
7.
Hasse B, Tarr PE, Marques-Vidal P, Waeber G, Preisig M, Mooser V, et al: Strong impact of smoking on multimorbidity and cardiovascular risk among human immunodeficiency virus-infected individuals in comparison with the general population. Open Forum Infect Dis 2015; 2: 108–109.
8.
Currier JS, Kendall MA, Henry WK, Alston-Smith B, Torriani FJ, Tebas P, et al: Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. AIDS 2007; 21: 1137–1145.
9.
Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al: Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 2010; 24: 1228–1230.
10.
van Velzen JE, Schuijf JD, de Graaf FR, Boersma E, Pundziute G, Spanó F, et al: Diagnostic performance of non-invasive multidetector computed tomography coronary angiography to detect coronary artery disease using different endpoints: detection of significant stenosis versus detection of atherosclerosis. Eur Heart J 2011; 32: 637–645.
11.
Post WS, Budoff M, Kingsley L, Palella FJ, Witt MD, Li X, et al: Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med 2014; 160: 458–467.
12.
Lai H, Moore R, Celentano DD, Gerstenblith G, Treisman G, Keruly JC, et al: HIV infection itself may not be associated with subclinical coronary artery disease among African Americans without cardiovascular symptoms. J Am Heart Assoc 2016; 5: 1–17.
13.
Thomas GP, Li X, Post WS, Jacobson LP, Witt MD, Brown TT, et al: Associations between antiretroviral use and subclinical coronary atherosclerosis. AIDS 2016; 30: 2477–2486.
14.
Tarr PE, Ledergerber B, Calmy A, Doco-Lecompte T, Marzel A, Weber R, et al: Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative persons. Eur Heart J 2018, DOI: 10.1093/eurheartj/ehy163–.
15.
Zanet DL, Thorne A, Singer J, Maan EJ, Sattha B, Le Campion A, et al: Association between short leukocyte telomere length and HIV infection in a cohort study: no evidence of a relationship with antiretroviral therapy. Clin Infect Dis 2014; 58: 1322–1332.
16.
Jiménez VC, Wit FWNM, Joerink M, Maurer I, Harskamp AM, Schouten J, et al: T-cell activation independently associates with immune senescence in HIV-infected recipients of long-term antiretroviral treatment. J Infect Dis 2016; 214: 216–225.
17.
Gonzalez-Serna A, Ajaykumar A, Gadawski I, Muñoz-Fernández MA, Hayashi K, Harrigan PR, et al: Rapid decrease in peripheral blood mononucleated cell telomere length after HIV seroconversion, but not HCV seroconversion. J Acquir Immune Defic Syndr 2017; 76: 29–32.
18.
O’Donnell CJ, Demissie S, Kimura M, Levy D, Gardner JP, White C, et al: Leukocyte telomere length and carotid artery intimal medial thickness: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2008; 28: 1165–1171.
19.
Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, et al: Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013; 14: 195–207.
20.
Obel N, Omland LH, Kronborg G, Larsen CS, Pedersen C, Pedersen G, et al: Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One 2011; 6: 1–6.
21.
Gueler A, Moser A, Calmy A, Günthard HF, Bernasconi E, Furrer H, et al: Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population. AIDS 2017; 31: 427–436.
22.
Mdodo R, Frazier EL, Dube SR, Mattson CL, Sutton MY, Brooks JT, et al: Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States. Ann Intern Med 2015; 162: 335–314.
23.
Huber M, Ledergerber B, Sauter R, Young J, Fehr J, Cusini A, et al: Outcome of smoking cessation counselling of HIV-positive persons by HIV care physicians. HIV Med 2012; 13: 387–397.
24.
Brown TT, Qaqish RB: Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20: 2165–2174.
25.
Sharma A, Shi Q, Hoover DR, Anastos K, Tien PC, Young MA, et al: Increased fracture incidence in middle-aged HIV-infected and HIV-uninfected women. J Acquir Immune Defic Syndr 2015; 70: 54–61.
26.
Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, Gulanski B, et al: Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One 2011; 6: 1–6.
27.
Junier T, Rotger M, Biver E, Ledergerber B, Barcelo C, Bartha I, et al: Contribution of genetic background and clinical risk factors to low-trauma fractures in human immunodeficiency virus (HIV)-positive persons: the Swiss HIV Cohort Study. Open Forum Infect Dis 2016; 3: 1–6.
28.
Borges ÁH, Hoy J, Florence E, Sedlacek D, Stellbrink H-J, Uzdaviniene V, et al: Antiretrovirals, fractures, and osteonecrosis in a large international HIV cohort. Clin Infect Dis 2017; 64: 1413–1421.
29.
Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P: Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS 2012; 26: 825–831.
30.
Bernardino JI, Mocroft A, Mallon P, Wallet C, Gerstoft J, Russel C, et al: Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. Lancet HIV 2015; 2: 464–473.
31.
Brown TT, Moser C, Currier JS, Ribaudo HJ, Rothenberg J, Kelesidis T, et al: Changes in bone mineral density after initiation of antiretroviral treatment with tenofovir disoproxil fumarate/emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir, or raltegravir. J Infect Dis 2015; 212: 1241–1249.
32.
Raffi F, Orkin C, Clarke A, Slama L, Gallant J, Daar E, et al: Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults. J Acquir Immune Defic Syndr 2017; 75: 1–6.
33.
Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, et al: Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis 2013; 207: 1359–1369.
34.
Kimmel PL, Barisoni L, Kopp JB: Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. Ann Intern Med 2003; 139: 214–226.
35.
Mocroft A, Ryom L, Reiss P, Furrer H, d’Arminio Monforte A, Gatell J, et al: A comparison of estimated glomerular filtration rates using Cockcroft-Gault and the chronic kidney disease epidemiology collaboration estimating equations in HIV infection. HIV Med 2014; 15: 144–152.
36.
Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, et al: Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011; 53: 1130–1139.
37.
Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, et al: Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis 2014; 59: 1787–1797.
38.
Dubé MP, Komarow L, Mulligan K, Grinspoon SK, Parker RA, Robbins GK, et al: Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. J Acquir Immune Defic Syndr 2007; 45: 508–514.
39.
McComsey GA, Moser C, Currier J, Ribaudo HJ, Paczuski P, Dubé MP, et al: Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s. Clin Infect Dis 2016; 62: 853–862.
40.
Tebas P, Zhang J, Hafner R, Tashima K, Shevitz A, Yarasheski K, et al: Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110. J Antimicrob Chemother 2009; 63: 998–1005.
41.
Hasse B, Iff M, Ledergerber B, Calmy A, Schmid P, Hauser C, et al: Obesity trends and body mass index changes after starting antiretroviral treatment: the Swiss HIV cohort study. Open Forum Infect Dis 2014; 1: 1–9.
42.
Erlandson KM, Zhang L, Lake JE, Schrack J, Althoff K, Sharma A, et al: Changes in weight and weight distribution across the lifespan among HIV-infected and -uninfected men and women. Medicine 2016; 95: 1–9.
43.
Sahakyan KR, Somers VK, Rodriguez-Escudero JP, Hodge DO, Carter RE, Sochor O, et al: Normal-weight central obesity: implications for total and cardiovascular mortality. Ann Intern Med 2015; 163: 827–835.
44.
Simioni S, Cavassini M, Annoni J-M, Rimbault Abraham A, Bourquin I, Schiffer V, et al: Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24: 1243–1250.
45.
Heaton RK, Franklin DR, Deutsch R, Letendre S, Ellis RJ, Casaletto K, et al: Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis 2015; 60: 473–480.
46.
Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al: Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: 1789–1799.
47.
Wright EJ, Grund B, Robertson K, Brew BJ, Roediger M, Bain MP, et al: Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 2010; 75: 864–873.
48.
Metral M, Locatelli I, Brugger P, Gutbrod K, Cavassini M, Du Pasquier R, et al: Prevalence of neurocognitive disorders in a well-treated and aging HIV-cohortConference on Retroviruses and Opportunistic Infections, Seattle, WA, February 13–16, 2017. Abstract 362. (Internet) available from http://www.croiconference.org/sessions/prevalence-neurocognitive-disorders-well-treated-and-aging-swiss-hiv-cohort.
49.
Anderson AM, Muñoz-Moreno JA, McClernon DR, Ellis RJ, Cookson D, Clifford DB, et al: Prevalence and correlates of persistent HIV-1 RNA in cerebrospinal fluid during antiretroviral therapy. J Infect Dis 2017; 215: 105–113.
50.
Althoff KN, McGinnis KA, Wyatt CM, Freiberg MS, Gilbert C, Oursler KK, et al: Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. Clin Infect Dis 2015; 60: 627–638.
51.
Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al: Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53: 1120–1126.
52.
Kooij KW, Wit FWNM, Schouten J, van der Valk M, Godfried MH, Stolte IG, et al: HIV infection is independently associated with frailty in middle-aged HIV type 1-infected individuals compared with similar but uninfected controls. AIDS 2016; 30: 241–250.
53.
Althoff KN, Jacobson LP, Cranston RD, Detels R, Phair JP, Li X, et al: Age, comorbidities, and AIDS predict a frailty phenotype in men who have sex with men. J Gerontol A Biol Sci Med Sci 2014; 69: 189–198.
54.
Schrack JA, Jacobson LP, Althoff KN, Erlandson KM, Jamieson BD, Koletar SL, et al: Effect of HIV-infection and cumulative viral load on age-related decline in grip strength. AIDS 2016; 30: 2645–2652.
55.
Marzolini C, Back D, Weber R, Furrer H, Cavassini M, Calmy A, et al: Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother 2011; 66: 2107–2111.
56.
Wooten JM: Pharmacotherapy considerations in elderly adults. South Med J 2012; 105: 437–445.
57.
Albrecht S, Ihmsen H, Hering W, Geisslinger G, Dingemanse J, Schwilden H, et al: The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther 1999; 65: 630–639.
58.
O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P: STOPP/START criteria for potentially inappropriate prescribing in older people. Age Ageing 2015; 44: 213–218.
59.
Kamal S, Bugnon O, Cavassini M, Schneider MP: HIV-infected patients beliefs about their chronic co-treatments in comparison with their combined antiretroviral therapy. HIV Med 2018; 19: 49–58.
60.
Overton ET, Chan ES, Brown TT, Tebas P, McComsey GA, Melbourne KM, et al: Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation. Ann Intern Med 2015; 162: 815–824.
61.
Cahn P, Andrade-Villanueva J, Arribas JR, Gatell JM, Lama JR, Norton M, et al: Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis 2014; 14: 572–580.
62.
Arribas JR, Girard P-M, Landman R, Pich J, Mallolas J, Martínez-Rebollar M, et al: Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis 2015; 15: 785–792.
63.
Buzzi M, Wandeler G, Anderegg N, Sculier D, Egger M, Calmy A, et al: Dolutegravir-based simplified maintenance therapy in HIV-infected patients – a systematic review and meta-analysis. European AIDS Conference, Milan, Italy, 2017.
64.
Burgess MJ, Zeuli JD, Kasten MJ: Management of HIV/AIDS in older patients; drug/drug interactions and adherence to antiretroviral therapy. HIV AIDS (Auckl) 2015; 7: 251–264.
65.
Nachega JB, Hsu AJ, Uthman OA, Spinewine A, Pham PA: Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population. AIDS 2012; 26(suppl 1):S39–S53.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.